Cubist Pharmaceuticals CEO Interviewed On CEOCast.com.Business Editors/Health/Medical Writers BIOWIRE2K LEXINGTON, Mass.--(BUSINESS WIRE)--March 15, 2004 Cubist Pharmaceuticals, Inc. (Nasdaq: CBST CBST Center for Biophotonics Science and Technology CBST Congregation Beth Simcha Torah (NYC) CBST Complete Binary Search Tree ) today announced that its President and Chief Executive Officer, Michael W. Bonney, was recently interviewed by CEOCast.com. CEOCast.com (www.CEOCast.com) is the premier source of original and syndicated streamlining broadcast interviews of Chief Executive Officers at public and private news-making companies. Organized by industry, its analysts average over 15 years' experience covering and evaluating Wall Street's leading companies. CEOCast's programming is distributed to millions of online investors at over 700 financial Web sites as well as to more than 20,000 portfolio managers, buy-side analysts, and traders at more than 3300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions. The interview may be accessed by free registration at www.CEOCast.com and through the Events Calendar section of www.cubist.com. The interview will be archived, and will be accessible for five business days on CEOCast's website. About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of drugs that meet significant unmet medical needs. Since its founding in 1992, Cubist has been exclusively focused on exploiting business and product opportunities in the antiinfective marketplace. In the U.S., Cubist markets Cubicin(TM) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides, for the indication of complicated skin and skin structure infections caused by Gram-positive bacteria. Cubicin(TM) is currently the only once-daily bactericidal bactericidal /bac·te·ri·ci·dal/ (bak-ter?i-si´d'l) destructive to bacteria. Bactericidal An agent that destroys bacteria (e.g. antibiotic approved in the U.S. with activity against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus methicillin-resistant Staphylococcus aureus Methicillin-aminoglycoside resistant Staphylococcus aureus, MRSA An organism with multiple antibiotic resistances–eg, aminoglycosides, chloramphenicol, clindamycin, erythromycin, rifampin, tetracycline, (MSSA MSSA Methicillin-Sensitive Staphylococcus Aureus MSSA Microscopy Society of Southern Africa MSSA Maryland Saltwater Sportfishermen's Association MSSA Military Selective Service Act MSSA Mid-South Sociological Association MSSA Minnesota Social Service Association and MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. ). Cubist's pre-clinical pipeline includes an oral version of ceftriaxone ceftriaxone /cef·tri·ax·one/ (cef?tri-ak´son) a semisynthetic, ß–resistant, third-generation cephalosporin effective against a wide range of gram-positive and gram-negative bacteria, used as the sodium salt. (OCTX), a broad-spectrum cephalosporin cephalosporin (sĕf'əlōspôr`ĭn), any of a group of more than 20 antibiotics derived from species of fungi of the genus Cephalosporium and closely related chemically to penicillin. Cephalosporins, e.g. antibiotic, and other novel members of the lipopeptide class. Cubist is headquartered in Lexington, MA. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion